logowsbdaily | Thu, 21 Oct 2021 07:34:41 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Kintara Therapeutics, Inc.
(KTRA)

Kintara Therapeutics, Inc.
12707 High Bluff Drive
Suite 200
San Diego, CA 92130
United States
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic t... Read More

Summary & Charts

Price$ 1.02+0.17 (+20%)
Day's Range$ 0.80 - 1.10 
Previous Close$ 0.85
Market Cap$ 42.82M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqCM
IndustryBiotechnology
SectorHealthcare
Volume12.12M
Avg. Volume (20 day)4.30M
Rel. Volume (20 day)2.82
Rel. Volume (3 month)8.50
RatingBNeutral
DCFN/AStrong Buy
Debt/Equity27.99 %Neutral
ROE81775.13 %Strong Sell
ROA67246.08 %Strong Sell
P/E0.00 %Sell
P/B2.82 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Oct 19, 2021$ 0.83$ 1.10$ 0.80$ 1.02+0.1712,115,4202.828.502
Oct 18, 2021$ 0.87$ 0.93$ 0.82$ 0.85-0.021,258,8290.341.01
Oct 15, 2021$ 0.91$ 0.94$ 0.84$ 0.86-0.042,115,2190.581.74
Oct 14, 2021$ 1.00$ 1.01$ 0.87$ 0.91-0.094,845,6401.354.021
Oct 13, 2021$ 1.02$ 1.08$ 0.93$ 1.00+0.049,012,0952.707.955
Oct 12, 2021$ 0.87$ 0.99$ 0.85$ 0.96+0.126,454,7872.226.303
Oct 11, 2021$ 0.77$ 0.86$ 0.77$ 0.83+0.074,026,6291.553.26
Oct 08, 2021$ 0.79$ 0.80$ 0.76$ 0.77-0.03903,7040.370.77
Oct 07, 2021$ 0.78$ 0.82$ 0.77$ 0.80+0.042,914,1801.222.51
Oct 06, 2021$ 0.75$ 0.80$ 0.74$ 0.76-0.021,636,3360.731.45
Oct 05, 2021$ 0.79$ 0.83$ 0.74$ 0.78-0.023,936,7681.813.52
Oct 04, 2021$ 0.85$ 0.86$ 0.78$ 0.80-0.033,143,2081.592.911
Oct 01, 2021$ 0.88$ 0.90$ 0.83$ 0.83-0.032,451,0081.342.33
Sep 30, 2021$ 0.83$ 0.90$ 0.82$ 0.86+0.044,383,2742.554.251
Sep 29, 2021$ 0.89$ 0.89$ 0.80$ 0.82-0.053,865,3762.553.932
Sep 28, 2021$ 0.90$ 0.97$ 0.87$ 0.87-0.017,555,2705.678.012
Sep 27, 2021$ 0.91$ 0.92$ 0.88$ 0.882,892,3343.003.41
Sep 24, 2021$ 1.00$ 1.01$ 0.88$ 0.88-0.247,778,0519.399.52
Sep 23, 2021$ 1.22$ 1.26$ 1.06$ 1.12-0.122,457,3845.563.451
Sep 22, 2021$ 1.35$ 1.53$ 1.22$ 1.24-0.082,194,5926.743.202

News

The latest news about Kintara Therapeutics, Inc. (KTRA).

Pulse2 | 2021-10-12 11:28:36
The stock price of Kintara Therapeutics Inc (NASDAQ: KTRA) increased by over 20% this past week. This is why it happened.
Proactive Investors | 2021-10-01 09:29:44
Kintara Therapeutics Inc, an oncology-focused, clinical-stage biopharmaceutical company received a ‘Buy' rating from Aegis Capital.  The analysts noted the biotech firm, which is developing VAL-083 for the treatment of glioblastoma multiforme (GBM) and REM-001 for the treatment of cutaneous metastatic breast cancer has several catalysts ahead that could lead to company growth.
Benzinga | 2021-09-30 07:16:15
Kintara Therapeutics(NASDAQ:KTRA) stock fell by 5.89% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 28, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Proactive Investors | 2021-09-29 09:53:07
Kintara Inc, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reports that it closed its fiscal year on June 30 with cash and cash equivalents of about $10.5 million. In a statement, the company noted that its balance sheet as of September 28 grew even stronger as it closed on a registered direct offering, priced at-the-market under Nasdaq rules, raising about $15 million to help fund ongoing clinical studies and corporate working capital needs.
PRNewsWire | 2021-09-29 08:00:00
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2021 and provided a corporate update.
PRNewsWire | 2021-09-28 13:33:00
SAN DIEGO, Sept. 28, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with several healthcare-focused institutional investors of 12,000,000 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 12,000,000 shares of common stock, at a combined offering price of $1.25 per share and associated warrant.
Proactive Investors | 2021-09-24 09:02:57
Kintara Therapeutics Inc has entered into securities purchase agreements with certain healthcare-focused institutional investors to raise about $15 million in gross proceeds.  The company said it intends to use the net proceeds to fund its clinical studies, working capital, and other general corporate purposes.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2021-11-10AMC-0.14----------
2021-09-29BMO-0.16-0.1318.75%------
2021-05-14BMO-0.18-0.2327.77%------
2021-02-12BMO-0.14-0.2257.14%------
2020-11-12BMO-0.09-1.331377.77%------
2020-09-18BMO-0.12-0.33175%------
2020-05-13BMO-0.12-0.1741.66%------
2020-02-13BMO-0.17-0.1511.77%------

Top Discussions

These are the top discussions over the last 24-hours that mention the KTRA stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Fri, 30 Jul 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.